Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.

The drug combination inhibited both the AKT and MAPK pathways almost completely ( Figure 4 B), thereby evidencing a highly significant synergistic inhibition of cell proliferation, as indicated by the comparison with the theoretical interaction curve in the Bliss experimental model ( p < 0.001) ( Figure 4 C).

also in 132,142 other papers